DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: aprepitant

Summary for Generic Name: aprepitant

Tradenames:2
Patents:4
Applicants:2
NDAs:2
Drug Master File Entries: see list13
Suppliers: see list3
Therapeutic Class:Antiemetics

Clinical Trials for: aprepitant

Efficacy of Aprepitant (Emend®) in Children
Status: Recruiting Condition: Nausea; Vomiting; Childhood Cancer

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma

Topical Aprepitant in Prurigo Patients
Status: Recruiting Condition: Pruritus

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Status: Completed Condition: Postoperative Nausea and Vomiting

Aprepitant Effects on Oxycodone Response
Status: Completed Condition: Narcotic Abuse

Pharmacokinetic (PK) Characteristics and Anti-Inflammatory Effects of the NK-1R Antagonist, Aprepitant, In HIV-Infected Subjects With Undetectable Viral Load Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir-Containing Antiretroviral Therapy
Status: Recruiting Condition: HIV Infection

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029)
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting; Ovarian Cancer

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Status: Recruiting Condition: Chemotherapy Induced Nausea and Vomiting

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Mar 26, 2003RXYes8,258,132<disabled>YPREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Mar 26, 2003RXYes8,258,132<disabled>YPREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Mar 26, 2003RXYes6,096,742<disabled>YYTREATMENT OR PREVENTION OF EMESIS
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Mar 26, 2003RXYes5,719,147<disabled>YYTREATMENT OR PREVENTION OF EMESIS
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc